JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY) ›› 2016, Vol. 30 ›› Issue (5): 81-84.doi: 10.6040/j.issn.1673-3770.0.2016.319

Previous Articles     Next Articles

Obstructive sleep apnea hypopnea syndrome and Fibroblast growth factor 21.

LIANG Xiaohong, LI Yan, LI Chong   

  1. Department of Respiratory, the First Peoples Hospital of Changzhou/the Third affiliated Hospital of Soochow University, Changzhou 213003, Jiangsu, China
  • Received:2016-07-21 Online:2016-10-20 Published:2016-10-20

Abstract: The prevalence of OSAHS has been dramatically increasing during the last decade, which has become one of the major diseases that endangers human health. The pathogenesis of OSAHS is not yet fully clear. Some studies have shown that FGF21 is closely linked with OSAHS. The correlation between FGF21 and OSAHS will be discussed in this chapter.

Key words: Fibroblast growth factor 21, Glucose and lipid metabolism, Energy metabolism, Obstructive sleep apnea hypopnea syndrome

CLC Number: 

  • R766.7
[1] Nishimura T, Nakatake Y, Konishi M, et al. Identification of a novel FGF, FGF-21, preferentially expressed in the liver[J]. Biochim Biophys Acta, 2000, 1492(1):203-206.
[2] Iglesias P, Selgas R, Romero S, et al. Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21[J]. Eur J Endocrinol, 2012, 167(3):301-309.
[3] Nies V J, Sancar G, Liu W, et al. Fibroblast growth factor signaling in metabolic regulation[J]. Front Endocrinol(Lausanne), 2015, 6:193.
[4] Indrakusuma I, Sell H, Eckel J. Novel mediators of adipose tissue and muscle crosstalk[J]. Curr Obes Rep, 2015, 4(4):411-417.
[5] Owen B M, Mangelsdorf D J, Kliewer S A. Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21[J]. Trends Endocrinol Metab, 2015, 26(1):22-29.
[6] Zhao Y, Dunbar J D, Kharitonenkov A. FGF21 as a therapeutic reagent[J]. Adv Exp Med Biol, 2012, 728(2):214-228.
[7] So W Y, Leung P S. Fibroblast growth factor 21 as an emerging therapeutic target for Type 2 diabetes mellitus[J]. Med Res Rev, 2016, 36(4):672-704.
[8] Chau M D, Gao J, Yang Q, et al. Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway[J]. Proc Natl Acad Sci U S A, 2010, 107(28):12553-12558.
[9] 芮欣忆, 阮晓楠,周先锋,等.上海市浦东新区20~74岁居民超重、肥胖、中心性肥胖的现况调查及流行特征[J].中华内分泌代谢杂志, 2016, 32(3):206-212. RUI Xinyi, RUAN Xiaonan, ZHOU Xianfeng, et al. Prevalence and epidemic characteristic of overweight, obesity, and central obesity in Shanghai Pudong New[J]. Chin J Endocrinol Metab, 2016, 32(3):206-212.
[10] 中华医学会呼吸病学会睡眠呼吸障碍学组,阻塞性睡眠呼吸暂停低通气综合征诊治指南(2011年修订版)[J].中华结核和呼吸杂志,2012,35(1):9-12. Chinese Medical Association of respiratory disease sleep respiratory disorder group, Clinical Practice Guidelines on traetment of obstructive sleep apnea sydrome[J]. Chin J Tuber Resp Dis, 2012, 35(1):9-12.
[11] Parekh R, Green E, Majeed A. Obstructive sleep apnoea: quantifying its association with obesity and snoring[J]. Prim Care Respir J, 2012, 21(4):361-362.
[12] Romero-Corral A, Caples S M, Lopez-Jimenez F, et al. Interactions between obesity and obstructive sleep apnea: implications for treatment[J]. Chest, 2010, 137(3):711-719.
[13] Giralt M, Gavalda-Navarro A, Villarroya F. Fibroblast growth factor-21, energy balance and obesity[J]. Mol Cell Endocrinol, 2015, 418:66-73.
[14] Fisher F M, Chui P C, Antonellis P J, et al. Obesity is a fibroblast growth factor 21(FGF21)-resistant state[J]. Diabetes, 2010, 59(11):2781-2789.
[15] Reinehr T, Woelfle J, Wunsch R, et al. Fibroblast growth factor 21(FGF-21)and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis[J]. J Clin Endocrinol Metab, 2012, 97(6):2143-2150.
[16] Zhang J, Li Y. Fibroblast growth factor 21 analogs for treating metabolic disorders[J]. Front Endocrinol(Lausanne), 2015, 6:168.
[17] Hui P, Jia S, Ma W, et al. The clinical significance and changes of serum tumor necrosis factor and plasma endothelium in patients with OSAHS associated Type 2 diabetes mellites[J]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, 2016, 30(3):217-219, 225.
[18] Xu J, Long Y S, Gozal D, et al. Beta-cell death and proliferation after intermittent hypoxia: role of oxidative stress[J]. Free Radic Biol Med, 2009, 46(6):783-790.
[19] Fan H, Sun X, Zhang H, et al. Effect of metformin on fibroblast growth factor-21 levels in patients with newly diagnosed Type 2 diabetes[J]. Diabetes Technol Ther, 2016, 18(3):120-126.
[20] Adams A C, Halstead C A, Hansen B C, et al. LY2405319, an engineered FGF21 variant, improves the metabolic status of diabetic monkeys[J]. PLoS One, 2013, 8(6):e65763.
[21] Mu J, Pinkstaff J, Li Z, et al. FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents[J]. Diabetes, 2012, 61(2):505-512.
[22] Lin Z, Tian H, Lam K S, et al. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice[J]. Cell Metab, 2013, 17(5):779-789.
[23] Anker S D, von Haehling S, Germany R. Sleep-disordered breathing and cardiovascular disease[J]. Indian Heart J, 2016, 68(1):69-76.
[24] Cheng P, Zhang F, Yu L, et al. Physiological and pharmacological roles of FGF21 in cardiovascular diseases[J]. J Diabetes Res, 2016, 2016:1540267.
[25] Chow WS, Xu A, Woo YC, et al. Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors[J]. Arterioscler Thromb Vasc Biol, 2013, 33(10):2454-2459.
[26] Jin L, Lin Z, Xu A. Fibroblast growth factor 21 protects against atherosclerosis via fine-tuning the multiorgan crosstalk[J]. Diabetes Metab J, 2016, 40(1):22-31.
[27] Lin Z, Pan X, Wu F, et al. Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice[J]. Circulation, 2015, 131(21):1861-1871.
[28] Cuevas-Ramos D, Aguilar-Salinas C A. Modulation of energy balance by fibroblast growth factor 21[J]. Horm Mol Biol Clin Investig, 2016.
[29] Hanssen M J, Broeders E, Samms R J, et al. Serum FGF21 levels are associated with brown adipose tissue activity in humans[J]. Sci Rep, 2015, 5:10275.
[30] Takx R, Ishai A, Truong Q A, et al. Supraclavicular Brown adipose tissue FDG uptake and cardiovascular disease[J]. J Nucl Med, 2016, 57(8):1221-1225.
[1] LI Ling, WANG Chunling, ZHANG Li, LI Yanzhong.. Predictors of difficult airway in patients with obstructive sleep apnea-hypopnea syndrome during general anesthesia. [J]. J Otolaryngol Ophthalmol Shandong Univ, 2017, 31(6): 62-67.
[2] LIU Wenjun, YU Xueying, LÜ Dan, CHEN Zhenggang, ZHANG Yanqing, MEI Xubin, YANG Ke. Correlation between obstructive sleep apnea hypopnea syndrome and upper airway measurements of different genders. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2017, 31(4): 54-59.
[3] SHANG Wei. Interpretation of “The Third Edition of the International Classification of Sleep Disorders(ICSD)”. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2016, 30(5): 18-20.
[4] ZHU Yue, HUANG Zhichun, YANG Ming, ZHU Xin. The study of cognitive disorderin patients with obstructive sleep apnea hypopnea syndrome. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2016, 30(5): 68-74.
[5] YU Qingqing, TANG Jun, WANG Yuejian. A systemic review system to evaluate the effects of different tonsil and adenoid surgical methods on children with obstructive sleep apnea-hypopnea syndrome. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2016, 30(5): 42-48.
[6] LI Yanzhong. Obesity and obstructive sleep apnea. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2016, 30(5): 1-4.
[7] WANG Yan. Progress in the classification and treatment of sleep respiratory diseases in children. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2016, 30(5): 5-8.
[8] LI Jun-zheng, GAO Xiang, WU Gai-zhen, CHEN Sha, WANG Jie, TIAN Wen-dong, LI Xiang-ping. Application of harmonic scalpel in children with obstructive sleep apnea and hyponea syndrome [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2015, 29(1): 1-4.
[9] SU Yue, WANG Zhong-liang, ZENG Zhen. Three different operative methods in H-UPPP [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2015, 29(1): 5-7.
[10] LIANG Song-min1, GUO Yong-wei2, ZHAO Xia1. The diagnostic effectiveness of  portable monitors device  in obstructive sleep apnea hypopnea syndrome [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2014, 28(2): 22-25.
[11] LI Yong-qiang, ZHANG Wen-shan. Uvula-preserving uvulopalatopharyngoplasty  with two incisions under local anesthesia to treat moderate OSAHS caused by large tonsils [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2014, 28(1): 67-69.
[12] MA Guo-wei1, ZHANG Qing-quan2, ZHOU Wen-liang1. Correlation of hyoid position, minimal retroglossal cross-section area and severity of obstructive sleep apnea hypopnea syndrome [J]. J Otolaryngol Ophthalmol Shandong Univ, 2013, 27(6): 66-68.
[13] LIU Wen-jun1, TONG Lei1, LIU Fu-xue2, MEI Xu-bin1, LI Min1, QIU Jie1, WANG Guo-hua1, WU Yi-ping1, CHEN Zheng-gang1. Research on the upper airway structure of children with sleep apnea hypopnea syndrome by magnetic resonance imaging examination [J]. J Otolaryngol Ophthalmol Shandong Univ, 2013, 27(5): 47-51.
[14] XU Wei-wei, LI Jian-dong, LIU Chun-ning, ZHANG Zhi-li. Effects of H-UPPP on blood pressure and heart rhythm in OSAHS patients [J]. J Otolaryngol Ophthalmol Shandong Univ, 2013, 27(4): 11-13.
[15] LI Ji-zhou, HAN Li, SONG Jian-jing. Obstructive planes and therapeutic efficacy in severe obstructive sleeping hypopnea-apnea syndrome [J]. J Otolaryngol Ophthalmol Shandong Univ, 2013, 27(4): 14-16.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] ZHAO Li-min, NI Kun, WU Jia-li, CHEN Shu-mei, LI Xiao-yan. Etiology and treatment of inspiratory laryngeal stridor in infants[J]. J Otolaryngol Ophthalmol Shandong Univ, 2013, 27(2): 49 -51 .
[2] SHI Chun-sheng1, ZHANG Qing-quan2, WANG Qiang2, SUN Yan2, GE Chang-yi1. Application of flaps in the reconstruction of soft palate defects[J]. J Otolaryngol Ophthalmol Shandong Univ, 2013, 27(2): 86 -88 .
[3] ZHANG Ling1, SUN Chuan-yi1, XU An-ting2. 1 case of petrous apex cholesteatoma deafness patients[J]. J Otolaryngol Ophthalmol Shandong Univ, 2013, 27(2): 93 -94 .
[4] . [J]. J Otolaryngol Ophthalmol Shandong Univ, 2013, 27(4): 1 -3 .
[5] LUO Hui-xiu, FAN Chun-tao, DENG Yan-hua. Therapeutic effects of adenoidectomy and tonsillectomy in children with obstructive sleep apnea hypopnea syndrome[J]. J Otolaryngol Ophthalmol Shandong Univ, 2013, 27(4): 17 -20 .
[6] HAO Ying-juan1, YANG Qing-song2, ZHOU Yue-hua2, YI Sheng-ping1, ZHAI Chang-bin2. Characteristics of thin corneal flaps created with Wavelight FS200 femtosecond laser[J]. J Otolaryngol Ophthalmol Shandong Univ, 2013, 27(4): 26 -31 .
[7] WEN Hua-ming1, LI Hai-xiang2. Application of trianglar function method to calculate intra ocular lens power after myopic laser in situ keratomileusis[J]. J Otolaryngol Ophthalmol Shandong Univ, 2013, 27(5): 74 -76 .
[8] ZHU Jian, HE Qing-qing, ZHENG Lu-ming, FAN Zi-yi, ZHAO Guo-wei, HOU Lei, SHI Hou-bin. Clinical analysis for 57 re-operational cases of differentiated thyroid cancer[J]. J Otolaryngol Ophthalmol Shandong Univ, 2013, 27(6): 9 -12 .
[9] LI Shao-hua, SUN Yi-fan, LU Biao-qing. Application of double vascularized soft tissue flap in open radical mastoidectomy[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2014, 28(1): 6 -7 .
[10] WEI Xi-jian1, YIN Rui-lan2, GUO Xing3. Expression of a proliferation-inducing ligand in laryngeal squamous cell carcinoma[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2014, 28(1): 14 -16 .